Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 5, 2009, Pages 1570-1577

  Tung, Min Che ^a,c   Tsai, Chin Shaw Stella ^a,d   Tung, Jai Nien ^a   Tsao, Tang Yi ^a   Chen, Hung Chang ^b   Yeh, Kun Tu ^b   Liao, Ching Fong ^c   Jiang, Ming Chung ^a  

^a TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; GELATINASE A; PROTEIN CSE1L; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SCREENING; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN LOCALIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 66549089442     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0948     Document Type: Article

References (25)

1. Brenner DE, Normolle DP. Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum. Cancer Epidemiol Biomarkers Prev 2007;16:1918-1920 (Pubitemid 47621163)
2. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006;6:961-967
3. Zhang H, Chan DW. Cancer biomarker discovery in plasma using a tissue-targeted proteomic approach. Cancer Epidemiol Biomarkers Prev 2007;16:1915-1917 (Pubitemid 47621162)
4. Wang H, Li M, Lin W, et al. Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients. Cancer Epidemiol Biomarkers Prev 2007;16:789-795 (Pubitemid 46650583)
5. Skates SJ, Horick NK, Moy JM, et al. Pooling of case specimens to create standard serum sets for screening cancer biomarkers. Cancer Epidemiol Biomarkers Prev 2007;16:334-341 (Pubitemid 46383355)
6. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mänsson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1087-1097 (Pubitemid 46984943)
7. Selander KS, Brown DA, Sequeiros GB, et al. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev 2007;16:532-537 (Pubitemid 46548657)
8. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541-573
9. Ben-Yosef Y, Lahat N, Shapiro S, Bitterman H, Miller A. Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res 2002;90:784-791 (Pubitemid 34633894)
10. Nguyen M, Arkell J, Jackson CJ. Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles. J Biol Chem 1998;273:5400-5404 (Pubitemid 28108709)
11. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC Jr, Stack MS. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994;56:552-559 (Pubitemid 24094407)
12. Brinkmann U, Brinkmann E, Gallo M, Pastan I. Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Proc Natl Acad Sci U S A 1995;92:10427-10431
13. Jiang MC, Luo SF, Li LT, et al. Synergic CSE1L/CAS, TNFR-1, and p53 apoptotic pathways in combined interferon-γ/Adriamycin-induced apoptosis of Hep G2 hepatoma cells. J Exp Clin Cancer Res 2007;26:91-99 (Pubitemid 46650049)
14. Liao CF, Luo SF, Shen TY, et al. CSE1L/CAS, a microtubule-associated protein, inhibits Taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs. BMB Rep 2008;41:210-216
15. Liao CF, Luo SF, Tsai CS, Tsao TY, Chen SL, Jiang MC. CAS enhances chemotherapeutic drug-induced p53 accumulation and apoptosis: use of CAS for high-sensitivity anticancer drug screening. Toxicol Mech Method 2008;18:771-776 (Pubitemid 352790070)
16. Behrens P, Brinkmann U, Wellmann A. CSE1L/CAS: its role in proliferation and apoptosis. Apoptosis 2003;8:39-44. (Pubitemid 36133136)
17. Liao CF, Luo SF, Li LT, Lin CY, Chen YC, Jiang MC. CSE1L/CAS, the cellular apoptosis susceptibility protein, enhances invasion and metastasis but not proliferation of cancer cells. J Exp Clin Cancer Res 2008;27:15.
18. 2α. Biomed Pharmacother 2008, doi:10.1016/j.biopha.2008.07.094.
19. Kutay U, Bischoff FR, Kostka S, Kraft R, Gorlich D. Export of importin α from the nucleus is mediated by a specific nuclear transport factor. Cell 1997;90:1061-1071 (Pubitemid 27408520)
20. Pickett JA, Edwardson JM. Compound exocytosis: mechanisms and functional significance. Traffic 2006;7:109-116
21. Kwan JA, Schulze CJ, Wang W, et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 2004;18:690-692
22. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007;26:587-596 (Pubitemid 350180394)
23. Zigrino P, Löffek S, Mauch C. Tumor-stroma interactions: their role in the control of tumor cell invasion. Biochimie 2005;87:321-328 (Pubitemid 40387611)
24. Cedermark BJ, Blumenson LE, Pickren JW, Holyoke DE, Elias EG. The significance of metastases to the adrenal glands in adenocarcinoma of the colon and rectum. Surg Gynecol Obstet 1977;144:537-546 (Pubitemid 8195941)
25. Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? Gastroenterol Clin North Am 1990;19:793-810.